Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 13:25:00 2024-07-16 EDT			5-day change	1st Jan Change
6.215 ^USD	+3.24%		+22.95%	+119.22%

07-01	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Comp Value Index	CI
07-01	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Completeness Index	CI

BLACK DIAMOND THERAPEUTICS, INC. : Other Events (form 8-K)

January 10, 2022 at 10:48 am

Item 8.01. Other Events.




BDTX-1535

On January 10, 2022, Black Diamond Therapeutics, Inc. (the "Company") announced that the US Food and Drug Administration had allowed its Investigational New Drug application for BDTX-1535. The Company expects to initiate the Phase 1 study of BDTX-1535 in the first quarter of 2022 and expects to provide a clinical update in the second half of 2023.

Latest news about Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Comp Value Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Completeness Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Microcap Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Value Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Value Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Dynamic Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Comp Growth Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Index	06-30	CI
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Value Index	06-30	CI
Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	06-01	CI
HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	05-16	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	04-11	CI
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	04-08	MT
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	04-08	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI

Chart Black Diamond Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Companyâs MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.02 USD

Average target price

12.6 USD

Spread / Average Target

+109.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BLACK DIAMOND THERAPEUTICS, INC.	+119.22%	339M
VERTEX PHARMACEUTICALS INCORPORATED	+20.41%	127B
REGENERON PHARMACEUTICALS, INC.	+24.34%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-18.57%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-16.07%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.73%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.83%	14.43B

Bio Therapeutic Drugs